ATE552837T1 - Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen - Google Patents
Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungenInfo
- Publication number
- ATE552837T1 ATE552837T1 AT06840105T AT06840105T ATE552837T1 AT E552837 T1 ATE552837 T1 AT E552837T1 AT 06840105 T AT06840105 T AT 06840105T AT 06840105 T AT06840105 T AT 06840105T AT E552837 T1 ATE552837 T1 AT E552837T1
- Authority
- AT
- Austria
- Prior art keywords
- high dose
- immune disorders
- treat immune
- dose oxazaphosphorine
- drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74217205P | 2005-12-02 | 2005-12-02 | |
PCT/US2006/061549 WO2007065167A1 (en) | 2005-12-02 | 2006-12-04 | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE552837T1 true ATE552837T1 (de) | 2012-04-15 |
Family
ID=37898760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06840105T ATE552837T1 (de) | 2005-12-02 | 2006-12-04 | Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen |
Country Status (6)
Country | Link |
---|---|
US (2) | US20070202077A1 (de) |
EP (2) | EP2345412A1 (de) |
AT (1) | ATE552837T1 (de) |
AU (1) | AU2006320162B2 (de) |
CA (1) | CA2631760A1 (de) |
WO (1) | WO2007065167A1 (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
EP2345412A1 (de) * | 2005-12-02 | 2011-07-20 | The Johns Hopkins University | Verwendung von hochdosierten Oxazaphosphorinmedikamenten zur Behandlung von Immunstörungen |
GB0614947D0 (en) * | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008156494A1 (en) * | 2006-11-03 | 2008-12-24 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders |
US20110123482A1 (en) * | 2007-10-01 | 2011-05-26 | The Johns Hopkins University | Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide |
US20110104100A1 (en) * | 2007-10-04 | 2011-05-05 | Medistem Laboratories, Inc. | Compositions and methods of stem cell therapy for autism |
WO2009067699A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for an oxazaphosphorine drug regimen |
US9026372B2 (en) | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
WO2009073146A2 (en) * | 2007-11-29 | 2009-06-11 | Celgene Corporation | Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
WO2009094456A2 (en) * | 2008-01-22 | 2009-07-30 | Johns Hopkins University | Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection |
WO2010011879A2 (en) * | 2008-07-25 | 2010-01-28 | The Johns Hopkins University | Methods and compositions for treating and preventing autoimmune diseases |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
EP2328920A2 (de) * | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Zielgerichtete, kostimulierende polypeptide und anwendungsverfahren zur behandlung von krebs |
US20120237472A1 (en) * | 2009-07-24 | 2012-09-20 | The Johns Hopkins University | Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents |
CA2769822C (en) | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
JP5876067B2 (ja) | 2010-11-23 | 2016-03-02 | アッヴィ・バハマズ・リミテッド | 選択的bcl−2阻害薬を用いた処置方法 |
US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
KR20140029469A (ko) | 2011-04-29 | 2014-03-10 | 셀렉타 바이오사이언시즈, 인크. | 세포독성 t 림프구 반응을 감소시키는 관용원성 합성 나노운반체 |
KR20160003219A (ko) | 2013-05-03 | 2016-01-08 | 셀렉타 바이오사이언시즈, 인크. | 감소 또는 증진된 약역학적 효과를 위한 관용유발 합성 나노담체 및 치료 거대분자 |
PL405506A1 (pl) * | 2013-09-30 | 2015-04-13 | Warszawski Uniwersytet Medyczny | Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2 |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
EP3171887A1 (de) | 2014-07-24 | 2017-05-31 | Reponex Pharmaceuticals APS | Zusammensetzungen mit faktor zur stimulierung von granulozyt-makrophagen-kolonien zur behandlung von entzündlicher darmerkrankung |
EA201790550A1 (ru) | 2014-09-07 | 2017-08-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов к корректирущим ген вирусным трансферным векторам |
WO2016102530A1 (en) * | 2014-12-22 | 2016-06-30 | Bergen Teknologioverføring As | Cyclic phosphoric acid derivative for the treatment of chronic fatigue syndrome |
US11395826B2 (en) * | 2015-11-20 | 2022-07-26 | Kyushu University, National University Corporation | Immunoregulatory agent |
EP3515478B1 (de) | 2016-09-21 | 2024-02-28 | Nextcure, Inc. | Antikörper für siglec-15 und verfahren zur verwendung davon |
KR20190124295A (ko) | 2017-03-11 | 2019-11-04 | 셀렉타 바이오사이언시즈, 인크. | 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물 |
MX2020002612A (es) | 2017-09-07 | 2020-07-13 | Univ Res Inst Inc Augusta | Anticuerpos de la proteina de muerte celular programada 1. |
CN112566934A (zh) | 2018-01-23 | 2021-03-26 | 奈斯科尔公司 | B7-h4抗体及其使用方法 |
WO2019169229A1 (en) | 2018-03-01 | 2019-09-06 | Nextcure, Inc. | Klrg1 binding compositions and methods of use thereof |
EP3911302A1 (de) | 2019-01-17 | 2021-11-24 | Georgia Tech Research Corporation | Arzneimittelabgabesysteme mit oxidierten cholesterinen |
US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
WO2023018904A1 (en) * | 2021-08-11 | 2023-02-16 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4537883A (en) * | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
US4841085A (en) * | 1986-06-30 | 1989-06-20 | Board Of Regents, University Of Texas System | Aldophosphamides |
US5055459A (en) * | 1986-06-30 | 1991-10-08 | Board Of Regents, The University Of Texas | Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates |
US5187266A (en) * | 1986-06-30 | 1993-02-16 | Board Of Regents The University Of Texas System | Antitumor aldophosphamide glycoside and dideoxyuridine derivatives |
US4753965A (en) * | 1987-04-09 | 1988-06-28 | Merrell Dow Pharmaceuticals, Inc. | Method of treating multiple sclerosis with chalcone derivatives |
JP2571119B2 (ja) * | 1988-03-08 | 1997-01-16 | 株式会社中埜酢店 | 細胞膜結合型アルデヒド脱水素酸素の構造遺伝子、これを含むプラスミド、形質転換した酢酸菌及び酢酸発酵法 |
US5036060A (en) * | 1988-07-25 | 1991-07-30 | Fujisawa Usa, Inc. | Cyclophosphamide |
US5649904A (en) * | 1988-10-07 | 1997-07-22 | Sandoz Ltd. | Method of treating cancer with a fully myeloablative regimen of chemotherapy, radiation or both |
US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
IL109168A0 (en) * | 1993-04-01 | 1994-06-24 | Univ Columbia | A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs |
US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
US5876956A (en) * | 1995-05-15 | 1999-03-02 | Johns Hopkins University School Of Medicine | Methods for identification or purification of cells containing an enzymatic intracellular marker |
EP1011694A4 (de) * | 1996-11-15 | 2000-11-15 | Baxter Int | Behandlung zur allogenen stammzelltransplantation |
US6255497B1 (en) * | 1997-04-29 | 2001-07-03 | The Endowment For Research In Human Biology, Inc. | Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse |
US6447767B1 (en) * | 1997-05-23 | 2002-09-10 | Hadasit Medical Research Services And Development Ltd. | Non-myeloablative tolerogenic treatment |
US6428782B1 (en) * | 1997-05-23 | 2002-08-06 | Hadasit Medical Research Services And Development Ltd. | Non-myeloablative tolerogenic treatment |
AU1585799A (en) * | 1997-11-14 | 1999-06-07 | General Hospital Corporation, The | Treatment of hematologic disorders |
IL122892A0 (en) * | 1998-01-11 | 1998-08-16 | Yeda Res & Dev | Pharmaceutical compositions comprising a thiocarbamate |
AU2903999A (en) * | 1998-03-12 | 1999-09-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
EP1077697B1 (de) * | 1998-05-12 | 2006-07-19 | The Endowment For Research In Human Biology, Inc. | Verfahren und testen verwendbar bei der behandlung von alkoholabhängigkeit oder -missbrauch |
ATE414783T1 (de) * | 1998-12-07 | 2008-12-15 | Univ Duke | Verfahren zur isolierung von stammzellen |
US6879959B1 (en) * | 2000-01-21 | 2005-04-12 | Quality Care Solutions, Inc. | Method of adjudicating medical claims based on scores that determine medical procedure monetary values |
WO2001065934A2 (en) * | 2000-03-09 | 2001-09-13 | Lee Walters | Applications of immune system tolerance to treatment of various diseases |
EP1280556A1 (de) * | 2000-05-05 | 2003-02-05 | Wisconsin Alumni Research Foundation | Zusammensetzungen und verfahren zum schutz von zellen während der chemotherpie und strahlentherapie |
US20020048584A1 (en) * | 2000-05-19 | 2002-04-25 | Pomerantz Roger J. | Method of treating residual HIV-I disease |
US6465436B2 (en) * | 2000-06-01 | 2002-10-15 | Mclean Hospital | Method for treating alcohol intoxication and alcohol abuse |
CN100420482C (zh) * | 2000-11-03 | 2008-09-24 | 精达制药公司 | ω干扰素在制备用于治疗丙型肝炎的药物中的用途 |
US20030007968A1 (en) * | 2001-01-26 | 2003-01-09 | Larsen Christian P. | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
US7335635B2 (en) * | 2001-02-21 | 2008-02-26 | Emory University | 14-3-3 binding molecules as sensitizers for anticancer therapies |
US20030031652A1 (en) * | 2001-04-16 | 2003-02-13 | Bernhard Hering | Systems and methods for inducing mixed chimerism |
US6936599B2 (en) * | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
US7432304B2 (en) * | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
US7037900B2 (en) * | 2001-10-12 | 2006-05-02 | Supergen, Inc. | Composition and method for treating graft-versus-host disease |
EP1542675A4 (de) * | 2002-06-27 | 2008-11-19 | Endowment For Res In Human Bio | N tzliche verbindungen zur hemmung von aldh |
WO2004022699A2 (en) * | 2002-09-05 | 2004-03-18 | Bharat Serums And Vaccines Ltd. | Liquid stable composition of oxazaphosphorine with mesna |
US7260249B2 (en) * | 2002-09-27 | 2007-08-21 | Confirma Incorporated | Rules-based approach for processing medical images |
PL1638589T3 (pl) * | 2003-05-14 | 2014-10-31 | Teva Pharmaceutical Industries Ltd | Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego |
US20060002930A1 (en) * | 2004-04-16 | 2006-01-05 | Genentech, Inc. | Treatment of disorders |
CA2571035A1 (en) * | 2004-06-25 | 2006-01-12 | Id Biomedical Corporation Of Quebec | Compositions and methods for treating neurological disorders |
US20060253263A1 (en) * | 2005-04-11 | 2006-11-09 | Meshkin Brian J | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy |
JP4837357B2 (ja) * | 2005-10-18 | 2011-12-14 | エルピーダメモリ株式会社 | 半導体記憶装置 |
EP2345412A1 (de) * | 2005-12-02 | 2011-07-20 | The Johns Hopkins University | Verwendung von hochdosierten Oxazaphosphorinmedikamenten zur Behandlung von Immunstörungen |
WO2009067699A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for an oxazaphosphorine drug regimen |
US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
-
2006
- 2006-12-04 EP EP11001548A patent/EP2345412A1/de not_active Withdrawn
- 2006-12-04 CA CA002631760A patent/CA2631760A1/en not_active Abandoned
- 2006-12-04 US US11/566,296 patent/US20070202077A1/en not_active Abandoned
- 2006-12-04 AU AU2006320162A patent/AU2006320162B2/en not_active Ceased
- 2006-12-04 AT AT06840105T patent/ATE552837T1/de active
- 2006-12-04 EP EP06840105A patent/EP1957082B1/de not_active Not-in-force
- 2006-12-04 WO PCT/US2006/061549 patent/WO2007065167A1/en active Application Filing
-
2010
- 2010-05-11 US US12/777,729 patent/US20110092462A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110092462A1 (en) | 2011-04-21 |
WO2007065167A1 (en) | 2007-06-07 |
AU2006320162A1 (en) | 2007-06-07 |
EP1957082B1 (de) | 2012-04-11 |
EP2345412A1 (de) | 2011-07-20 |
EP1957082A1 (de) | 2008-08-20 |
AU2006320162B2 (en) | 2013-07-25 |
US20070202077A1 (en) | 2007-08-30 |
CA2631760A1 (en) | 2007-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE552837T1 (de) | Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen | |
ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
ATE445415T1 (de) | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung | |
LTPA2016034I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
EA200802204A1 (ru) | Применение ингибиторов dpp iv | |
DE602006017071D1 (de) | Zusammensetzungen und verfahren zur behandlung von herzkrankheiten | |
ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
DE60331236D1 (de) | Orale zusammensetzungen zur behandlung von diabetes | |
DE602005010788D1 (de) | Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln | |
CR6620A (es) | Amino acidos biciclicos como agentes farmaceuticos | |
CR9181A (es) | Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa | |
ATE477811T1 (de) | Oxytocin zur behandlung von autismus und asperger-syndrom | |
ATE340568T1 (de) | Verwendung einer pharmazeutischen formulierung enthaltend milchsäure oder laktat und kalium zur behandlung von hirnödem und verletzungen des gehirns | |
EA200600921A1 (ru) | Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний | |
WO2010093993A3 (en) | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance | |
ATE442854T1 (de) | Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung | |
ATE437641T1 (de) | Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis | |
ATE484280T1 (de) | Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma | |
DE602005018179D1 (de) | Behandlung von krankheiten | |
ATE495750T1 (de) | Sulfatide zur behandlung von autoimmunkrankheiten | |
ATE408670T1 (de) | Autologous selbst-toleranz induzierende zellen monozytären ursprungs und ihren verwendung in artzneimitteln | |
ATE418558T1 (de) | Darstellung von 1-aza-2-oxadibenzoäe,hüazulenen und deren verwendung bei der herstellung pharmazeutischer formulierungen zur behandlung und prävention von krankheiten und erkrankungen des zentralen nervensystems | |
UA87139C2 (ru) | Способ лечения поражений ветвей тройничного нерва | |
RU2011150950A (ru) | Способ комплексного лечения рефракционной амблиопии больных миопией высокой степени | |
BRPI0402756A (pt) | método para o tratamento de distúrbios cognitivos |